SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
TVTX

Travere Therapeutics, Inc. (NASDAQ:TVTX)

US · Delayed Price · Currency is USD
Healthcare · Biotechnology
$47.00-$1.30 (-2.69%)
 
Market cap
$4.51B
Insider Score
Health Score
Analyst consensus
Listed since
Nov 8, 2012
Market Cap$4.51B+31.3%
Revenue (ttm)$651.03M+49.4%
Net Income-$121.51M-37.2%
EPS-$1.56-43.1%
Shares Out95.99M
PE Ration/a
Forward PE15.66
Dividendn/a
Ex-Dividend Daten/a
Volume1,329,582
Open$48.09
Previous Close$48.30
Day's Range$46.93 - $49.29
52-Week Range$22.59 - $68.73
Beta1.12
AnalystsBuy
Price Target$76.00(+61.70%)
Earnings DateFeb 18, 2027

About TVTX

Travere Therapeutics, Inc. is a biopharmaceutical company developing therapies for rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral, once-daily, non-immunosuppressive medication targeting two pathways of disease progression (endothelin-1 and angiotensin-II). Sparsentan received accelerated FDA approval in February 2023 and full approval in September 2024 to slow kidney function decline in adults with primary IgA nephropathy (IgAN) at risk of progression. In April 2026, the FDA approved FILSPARI to reduce proteinuria in adult and pediatric patients aged 8 and older with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome, making it the first and only FDA-approved medicine for FSGS. The company also markets Thiola and Thiola EC (tiopronin tablets) for cystinuria, a rare genetic disorder causing recurring kidney stones. Its pipeline includes pegtibatinase, an investigational enzyme replacement therapy for classical homocystinuria (HCU). Formerly Retrophin, Inc. (renamed November 2020), Travere is headquartered in San Diego, California, and incorporated in Delaware.

Address
3611 Valley Centre Drive, San Diego, CA, 92130, US
Market Cap
4.51 billion
Employees
497
Industrial Classification
Biotechnology

What Are Insiders Doing?

Open-market buy / sell balanceNet Selling
Sold
$52.30M
Bought
$0

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Analyst consensus

Moderate Buy
6 Buy0 Hold0 SellAvg target $78.00 (+66.0%)

6 firms rating TVTX in the last 3 months, one vote each. Issuer-paid research is not counted.

Financial Health Score
Fair
From TVTX’s reported statements · Q3 2026 (trailing 12 months)

Next catalysts

1 Day
-2.69%
5 Days
-6.75%
1 Month
-10.36%
6 Months
+5.78%
1 Year
+31.32%

$TVTX stock is featured in our Insider Score Rankings, and Insider Trades datasets.

→ All Stock Lists

Recently reported changes in TVTX holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by TVTX's directors and management

Net Shares Purchased by Insiders−700k−350k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

TVTX Estimated quarterly lobbying spending

Source: U.S. Senate LDA

TVTX Revenue by Segment

$220.20MTotal
FILSPARI$200.19M90.92%
Tiopronin products$20.00M9.08%

As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)

U.S. Patents

New TVTX patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to TVTX from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in TVTX

VTIVanguard Morningstar Total Stock Market ETF$118.98M
IWMiShares Russell 2000 ETF$112.70M
XBIState Street SPDR S&P Biotech ETF$110.47M
VXFVanguard Extended Market ETF$53.91M
VBVanguard Morningstar Small-Cap ETF$53.20M
IWOiShares Russell 2000 Growth ETF$40.74M

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from TVTX’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
60% of score
0
Analyst Ratings
40% of score
99
News & Sentiment
No data yet
—

Recent Insider Activity

Buys
0
Sells
16
Buy Value
$0
Distinct Buyers
0

Insider Score Trend Over Time

-37.0 since Aug 21
0255075100Aug 21 — Insider Score 37.0Aug 22 — Insider Score 37.0Aug 23 — Insider Score 37.0Aug 24 — Insider Score 37.0Aug 25 — Insider Score 37.0Aug 26 — Insider Score 37.0Aug 27 — Insider Score 37.0Aug 28 — Insider Score 37.0Aug 29 — Insider Score 37.0Aug 30 — Insider Score 37.0Aug 31 — Insider Score 37.0Sep 1 — Insider Score 0.0Sep 2 — Insider Score 0.0Sep 3 — Insider Score 0.0Sep 4 — Insider Score 0.0Sep 5 — Insider Score 0.0Sep 6 — Insider Score 0.0Sep 7 — Insider Score 0.0Sep 8 — Insider Score 0.0Sep 9 — Insider Score 0.0Sep 10 — Insider Score 0.0Sep 11 — Insider Score 0.0Sep 12 — Insider Score 0.0Sep 13 — Insider Score 0.0Sep 14 — Insider Score 0.0Sep 15 — Insider Score 0.0Sep 16 — Insider Score 0.0Sep 17 — Insider Score 0.0Sep 18 — Insider Score 0.0Sep 19 — Insider Score 0.0Sep 20 — Insider Score 0.0Sep 21 — Insider Score 0.0Sep 22 — Insider Score 0.0Sep 23 — Insider Score 0.0Sep 24 — Insider Score 0.0Sep 25 — Insider Score 0.0Sep 26 — Insider Score 0.0Sep 27 — Insider Score 0.0Sep 28 — Insider Score 0.0Sep 29 — Insider Score 0.0Sep 30 — Insider Score 0.0Oct 1 — Insider Score 0.0Oct 2 — Insider Score 25.0Oct 3 — Insider Score 0.0Oct 4 — Insider Score 0.0Aug 21Sep 12Oct 4

Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

LFSCF/M Emerald Life Sciences Innovation ETF5.67%
SBIOALPS Medical Breakthroughs ETF3.17%
HELXFranklin Genomic Advancements ETF2.41%
PJPInvesco Pharmaceuticals ETF2.34%
PTHInvesco Dorsey Wright Healthcare Momentum ETF2.08%
AFSCabrdn Focused U.S. Small Cap Active ETF1.66%
TDNAT. Rowe Price Biotech ETF1.39%
CTAGCalamos Timpani Active SMID Growth ETF1.36%
MMSCFirst Trust Multi-Manager Small Cap Opportunities ETF1.30%
BBPVirtus Biotech ETF1.29%
SPITF/m Emerald Special Situations ETF1.25%
XBIState Street SPDR S&P Biotech ETF1.17%

Weight is the stock’s share of each fund’s holdings.